AbCellera Biologics Q1 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate, Sales $9.954M Miss $10.836M Estimate
AbCellera Biologics Q1 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate, Sales $9.954M Miss $10.836M Estimate
abCellera Biologics 2024年第一季度GAAP每股收益美元（0.14美元）超過預期（0.16美元），銷售額爲995.4萬美元，未達到1083.6萬美元的預期
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. The company reported quarterly sales of $9.954 million which missed the analyst consensus estimate of $10.836 million by 8.14 percent. This is a 18.36 percent decrease over sales of $12.192 million the same period last year.
ABCellera Biologics（納斯達克股票代碼：ABCL）公佈的季度虧損爲每股0.14美元，比分析師共識估計的美元（0.16美元）高出12.5％。該公司公佈的季度銷售額爲995.4萬美元，比分析師共識估計的1083.6萬美元低8.14％。這比去年同期的1219.2萬美元的銷售額下降了18.36％。